• Policy
• SGLT2 Domestic new drug/combined drug market
• by Lee, Tak-Sun Apr 20, 2023 05:58am

• Policy
• NA presses for Targrisso’s reimb in the first line
• by Lee, Jeong-Hwan Apr 20, 2023 05:58am

• Policy
• Enhertu, re-discussing with supplementary materials
• by Lee, Tak-Sun Apr 19, 2023 05:51am

• Policy
• MSD Welireg is about to be approved in Korea
• by Lee, Hye-Kyung Apr 19, 2023 05:51am

• Policy
• As a result of the PMS of Entresto·Xnepri,
• by Lee, Hye-Kyung Apr 18, 2023 05:38am

• Policy
• Kyowa Kirin accepted the evaluation results for Nephoxil
• by Lee, Tak-Sun Apr 17, 2023 05:58am

• Policy
• Obesity treatment Mounjaro, soon to launch in Korea
• by Lee, Hye-Kyung Apr 14, 2023 05:49am

• Policy
• SGLT2+DPP4 combinations are to be released next month
• by Lee, Tak-Sun Apr 14, 2023 05:49am

• Policy
• Domestic approval of Pemazyre is imminent
• by Lee, Hye-Kyung Apr 13, 2023 05:45am

• Policy
• Decreased commitment to production/sales/new generics
• by Lee, Jeong-Hwan Apr 13, 2023 05:45am